ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ACHN Achillion Pharmaceuticals Inc

6.76
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Achillion Pharmaceuticals Inc NASDAQ:ACHN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.76 6.93 6.75 0 01:00:00

Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference

28/04/2016 11:05am

GlobeNewswire Inc.


Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Achillion Pharmaceuticals Charts.

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 41st Annual Health Care Conference on Thursday, May 5, 2016 at 1:30 p.m. EDT at The InterContinental Hotel in Boston, MA.

The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company seeks to employ a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement inhibitors. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.

Investors:
Glenn Schulman
Achillion Pharmaceuticals, Inc.
Tel. (203) 752-5510
gschulman@achillion.com

Media:
Liz Power
Achillion Pharmaceuticals, Inc.
Tel: (203) 752-5509
lpower@achillion.com

1 Year Achillion Pharmaceuticals Chart

1 Year Achillion Pharmaceuticals Chart

1 Month Achillion Pharmaceuticals Chart

1 Month Achillion Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock